Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 30 at 2:00 PM EDT

Register Free →

DoW Reconstructive Transplant, Investigator-Initiated Research Award

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The fiscal year 2026 Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award, administered by the Defense Health Agency, supports studies aimed at advancing the science and clinical practice of vascularized composite allotransplantation (VCA). The program targets improvements in access, safety, and quality of life for catastrophically injured Service Members, Veterans, and the general public. Eligible research spans from basic and translational phases to preclinical animal models and clinical research in human subjects, though clinical trials are explicitly excluded. Awards are capped at 1.0 million dollars with a maximum period of performance of three years. Applicants must demonstrate military relevance and align their projects with at least one FY26 RTRP Focus Area. Proposals require a rigorous study design, a strong statistical plan, and the inclusion of relevant preliminary or published data. The selection process involves a two-tier review consisting of a technical peer review and a programmatic review. Key submission requirements include active registration in SAM.gov, eBRAP, and Grants.gov, with a pre-application deadline of October 21, 2026, and a full application deadline of November 4, 2026. Required documentation includes a Statement of Work, Impact Statement, Military Relevance document, and disclosure of foreign affiliations for all key personnel.

General Info

DHA FY26 RTRP awards up to $1M for VCA research over three years.

Agency

Department Of Defense → Defense Health Agency Contracting Activity - DhacaView Agency

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(1)

HT942526RTRPIIRA - Reconstructive Transplant Research Program Investigator-Initiated Research Award

PDFpresolicitation

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency Contracting Activity - Dhaca
Contacts1 person available
OfficeUSA
Organization / Agency
Department Of Defense → Defense Health Agency Contracting Activity - Dhaca
View Agency Profile
Office AddressUSA

Full Description

Show more

Summary: The fiscal year 2026 (FY26) Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award supports studies that have the potential to make an important contribution to reconstructive transplant research, patient care, and/or quality of life. All projects must demonstrate solid scientific rationale with military-relevant utility. The Investigator-Initiated Research Award does not support clinical trials.


Distinctive Features:

·        Scope: Applications may focus on any phase of research from basic through translational, including preclinical studies in animal models, and clinical research in human subjects or human anatomical substances.

·        Study Design and Feasibility: The study design should be rigorous and support maximal reproducibility and translational feasibility. A strong statistical plan with appropriate power analysis is important.

·        Impact: Project results should have the potential for long- and short-term impact on the reconstructive transplant research field and/or patient community. Projects should address at least one of the FY26 RTRP Focus Areas.

·        Preliminary Data: Preliminary and/or published data that are relevant to reconstructive transplantation and support the rationale for the proposed research must be included.

·        Military Relevance: All projects must be responsive to the health care needs of military Service Members and/or Veterans recovering from traumatic injury, and/or their Family members, caregivers, or clinicians, as well as the general public. Collaboration with military researchers and clinicians is encouraged but not required.

Similar Contracts

Same NAICS industry code

More opportunities from Department Of Defense → Defense Health Agency Contracting Activity - Dhaca

Same awarding agency

NAICS: 541715
Grant
DoW Breast Cancer, Breakthrough Award Levels 1 and 2
Solicitation # HT942526BCRPBTA122
The Defense Health Agency Contracting Activity is soliciting applications for the fiscal year 2026 Breast Cancer Research Program Breakthrough Award Levels 1 and 2 under solicitation HT942526BCRPBTA122. This program supports high-potential research aimed at achieving breakthroughs in breast cancer, with an expected total allotment of approximately 10.6 million dollars to fund roughly six applications. Funding Level 1 focuses on innovative, high-risk research in early stages of development to achieve proof of concept, while Funding Level 2 supports research validated by substantial preliminary or published data. The program also includes a Population Science Studies option within Level 2. Applications may be submitted by a single Principal Investigator or through a partnering PI option involving an Initiating PI and a Partnering PI. The maximum period of performance is three years for standard awards and four years for Population Science Studies. Funding limits vary by level and PI structure, ranging from 750,000 dollars for Level 1 single PI awards up to 3.35 million dollars for Level 2 Population Science partnering PI awards. Evaluation is based on scored criteria including impact, research strategy, feasibility, and personnel qualifications, with additional programmatic reviews for portfolio composition and innovation. Applicants must be registered in the System for Award Management and submit a two-step application process, with pre-applications due by November 4, 2026, and full applications due by November 18, 2026. Required documentation includes a project narrative, statement of work, and various abstracts, with strict adherence to PDF naming conventions and page limits.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

16 days ago

DEADLINE

in 2 months
View Details
NAICS: 541715
Grant
DoW Breast Cancer, Clinical Research Extension Award
Solicitation # HT942526BCRPCREA2
The Defense Health Agency Contracting Activity is soliciting applications for the fiscal year 2026 Breast Cancer Research Program Clinical Research Extension Award under solicitation HT942526BCRPCREA2. This grant opportunity supports research aimed at extending data collection, follow-up, and analysis of breast cancer clinical studies to mitigate knowledge loss resulting from early trial termination, limited patient follow-up, or suboptimal sample and data collection. The program emphasizes increasing the clinical relevance of patient participation and may include deeper molecular analysis of clinical samples. All applications must address at least one of the FY26 BCRP overarching challenges or provide a strong justification for an exception. The application process is a two-step submission requiring a pre-application Letter of Intent by November 4, 2026, and a full application by November 18, 2026. Submissions are handled via the Electronic Biomedical Research Application Portal for pre-applications and intramural organizations, while extramural organizations must use Grants.gov. The award allows for a single Principal Investigator or a partnering PI option involving an Initiating PI and a Partnering PI. A critical requirement is the inclusion of at least two breast cancer consumer advocates on the research team. The maximum period of performance is four years. Evaluation follows a two-tier system consisting of a peer review for technical merit and a programmatic review for relevance. Scored criteria include the project's impact on overarching challenges, research strategy and feasibility, the research sharing plan, and, for partnering PI options, the strength of the partnership. Required documentation for the full application includes a project narrative, statement of work, impact statement, and various abstracts. Organizations must maintain active registration in the System for Award Management and provide a unique entity identifier.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

16 days ago

DEADLINE

in 2 months
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS